Drugs / Universal CD19 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06485232 | Feb 2025 → Dec 2026 expected | chronic inflammatory demyelinating polyradiculoneuropathy, generalized myasthenia gravis, multiple sclerosis, neuromyelitis optica | Xuanwu Hospital, Beijing | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Universal CD19 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06485232 ↗ |
| Modality | Cell therapy | “Universal CD19 CAR-T” NCT06485232 ↗ |